IN BRIEF
- Billions have been wiped from CSL's valuation following profit downgrades and pressure from competition.
- Analysts say the healthcare giant now faces a "show me" moment, with doubts growing about its growth.
For years, CSL was seen as one of Australia's safest blue-chip investments — a healthcare giant trusted by super funds, retail investors and the broader market.
But in recent weeks, the biotech company's share price has suffered one of the sharpest falls in its history, wiping nearly $10 billion from its market value.
What kicked off that major price plunge was the company's announcement on 11 May, which revealed massive business write-downs and a downgrade of future profit expectations.
While the shock announcement rattled investors, the company's share price had been on a downward spiral long before that.
The events now raise a broader question: is this a temporary stumble for one of Australia's corporate champions, or a sign it has deeper problems?
Speaking to SBS On the Money on 11 May, Munjarra Capital chief executive Alex Pikoulas put it simply: "This is no longer the same company with the same outlook that everyone fell in love with years ago".
Investment analyst Richard Hemming from Under the Radar Report said many of the company's current problems could be traced back to acquisitions it had made, particularly the multi-billion-dollar purchase of kidney treatment business Vifor in 2022.
"They made some big acquisitions [which] haven't worked out," he said.
What happened to CSL?
The Melbourne-based biotechnology company stunned markets after it said on 11 May that it would book around US$5 billion (A$6.9 billion) in impairment charges against its Vifor business, which reduced its profit massively for the 2026 financial year.
In simple terms, an impairment means writing off parts of a business that are worth significantly less than previously thought.
CSL also warned that the expected growth it had projected would take longer to materialise than it had anticipated.
It had been hit by weaker vaccination demand in the United States after the pandemic-era surge faded, and has faced rising competition in iron deficiency treatments and ongoing pricing pressure in China's albumin market.
At the same time, higher plasma collection costs have squeezed margins, and a period of executive turnover and restructuring has added to investor uncertainty about the company's direction.
Hemming said those pressures had compounded broader concerns about whether CSL could ultimately deliver the growth investors had expected.
"There's more pressure on margins than they previously admitted," he said.
"China is not proving to be the growth engine that they anticipated."
Munjarra's Pikoulas said investors were also confronting the reality that CSL was operating in a far more competitive environment than the one that helped build its reputation over previous decades.
"A lot has changed, in particular the competitive environment they're facing, which has been a big contributor to these downgrades," he said.
He also said there was "a lot of uncertainty" at the top of the company, which is currently led by an interim chief executive while its chief commercial officer prepares to retire.
Why are investors so shocked?
Part of the reason investors have reacted so strongly was that CSL has long been viewed as one of Australia's safest and most reliable growth companies.
For years, investors were willing to pay a premium for CSL shares because they believed the company could consistently deliver strong long-term growth through its global healthcare businesses and research pipeline.
But Hemming said repeated downgrades had badly damaged investor confidence.
"What they've done is progressively ratchet down expectations," he said.
"Four profit downgrades in nine months — that is unbelievable."
He said the market's frustration was not only about weaker profits but also a growing disconnect between what management had previously promised investors and what the company was delivering.
"Now the market's saying: 'we don't trust you anymore'," he said.
"A lot of investing is about what people think about the future."
"When people have less confidence in what management are saying about the future, they're less trusting of the company."
Can CSL recover investor confidence?
Despite the turmoil, CSL has significant long-term strengths.
Hemming said the company's global business still has a lot of potential, even if investor confidence may take years to rebuild.
"The underlying assets of CSL, which is a global franchise business, still have a competitive edge globally," he said.
But he warned the company had shifted in the eyes of investors from a high-growth stock into a "value investment" or one with little growth.
Other analysts have debated over whether the market reaction had been excessive. They argue that if CSL can stabilise earnings, the company may eventually regain ground.
Hemming said the dramatic share sell-off had likely created opportunities for some investors, but warned confidence — and thus share price — would take time to rebuild. Just because a company's share price is lower doesn't make it attractive.
"There is an opportunity because there's such low expectation in the stock now," he said.
"But it won't necessarily be an opportunity where it rebounds quickly."
Company's fate matters beyond investors
CSL is one of the largest companies on the ASX, but its fate matters beyond direct share market investors.
The company has long been a major holding across many Australian superannuation portfolios, meaning millions of Australians may have indirect exposure through their retirement savings.
Hemming said large passive investment and superannuation funds had automatically reduced their holdings as the company's weighting in market indexes declined.
For now, he said, CSL needs to act — before there is a more permanent shift in how investors view the company's future.
"It's definitely a case of 'show me' time," he said.
"They need to deliver."
For the latest from SBS News, download our app and subscribe to our newsletter.
